U.S., Jan. 29 -- ClinicalTrials.gov registry received information related to the study (NCT06795906) titled 'A Safety, Pharmacokinetic, and Pharmacodynamic Study of Once Daily Inhaled AZD8630 in Adults With Asthma' on Jan. 22.
Brief Summary: This is a randomised, placebo-controlled, double-blinded, sponsor-unblinded study to assess the safety, pharmacokinetic (PK), and pharmacodynamic (PD) effect of AZD8630 in adult participants with asthma on medium-to-high dose inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA).
Study Start Date: Jan. 28
Study Type: INTERVENTIONAL
Condition:
Asthma
Intervention:
DRUG: AZD8630
AZD8630 will be administered via dry powder inhalation (DPI).
OTHER: Placebo
Placebo will be administered...